Role of PCSK9 Inhibitors in the Management of Patients with Familial Hypercholesterolemia Recognize the warning signs of Familial Hypercholesterolemia (FH) in patients who present with high cholesterol and learn to devise medical treatment plans in line with evidence-based guidelines for LDL-C management

Advancements in novel therapies and technologies, lifestyle medicine, multidisciplinary approaches that are driving improvements in outcomes and quality, and cardiovascular (CVD)/metabolic disease prevention.

Summary of guideline updates, clinical expertise, and new or emerging treatments for major chronic illnesses encountered daily in family practice medicine.

Provide insight on statin intolerance and discuss nonstatin treatment options as well as compare and contrast indications for the PCSK9 inhibitors.

Duchenne Muscular Dystrophy – An Expanding Lifespan This two session activity summarizes the differential diagnosis of DMD and applicable diagnostic approaches as well as assess the therapeutic potential of available and emerging treatment options for the management of DMD

Review the latest clinical trial data on PCSK9 inhibitors in reducing cardiovascular events in patients with hypercholesterolemia.

Using a case-based approach, apply CVOT data and current guideline recommendations to individualize glucose lowering therapy and reduce cardiovascular risk in patients with T2D.

Select appropriate AF patients for rate, rhythm, or ablation therapy in accordance with current guideline recommendations to optimize outcomes.

Discuss the latest clinical trial data available on nonstatin LDL-C–lowering agents and their position in treatment regimens for patients with elevated LDL-C levels